Results 211 to 220 of about 340,285 (357)

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao   +27 more
wiley   +1 more source

Inducible nitric oxide inhibition reduces intestinal ischemia-reperfusion injury via inhibition of neutrophil accumulation and oxidative stress in rats

open access: bronze, 2003
Tomohisa Takagi   +11 more
openalex   +1 more source

Resolution of Post-Lung Transplant Ischemia-Reperfusion Injury is Mediated via Resolvin D1-Alx/FPR2 and Maresin 1-LGR6 Receptor Signaling

open access: bronze, 2021
Victoria Leroy   +8 more
openalex   +1 more source

Cardiogenic shock mortality according to Aetiology in a Mediterranean cohort: Results from the Shock‐CAT study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1336-1345, April 2025.
Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García   +17 more
wiley   +1 more source

S-nitrosoglutathione preserves vasodilation and attenuates myocardial ischemia-reperfusion injury. [PDF]

open access: yesSci Rep
Guizoni DM   +5 more
europepmc   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen   +7 more
wiley   +1 more source

Transcranial direct-current stimulation protects against cerebral ischemia-reperfusion injury through regulating Cezanne-dependent signaling

open access: hybrid, 2021
Jing Cheng   +11 more
openalex   +1 more source

Home - About - Disclaimer - Privacy